UEMS Medical Specialty
Gastroenterology
Precision microbiome interventions, short-chain fatty acid (SCFA) delivery, enteric coating technologies, and gut–brain axis modulation for gastrointestinal and liver health.
16
dossiers
Post-GLP-1 Metabolic Optimization
Drug-Induced Nutrient Depletion (DIND): Molecular Mechanisms of Iatrogenic Deficiencies in Chronic Pharmacotherapy
Mitigating drug-induced nutrient depletion requires advanced CDMO solutions to formulate targeted nutritional support that is compatible with existing chronic pharmacotherapy and addresses diverse mechanistic pathways of depletion.
Precision Microbiome & Gut-Brain Axis
Hidden Pharmacodynamics of Pharmaceutical Formulations: Excipient, Impurity, and Oxidation Index Impact on Clinical Safety
Pharmaceutical and nutraceutical formulations often overlook the direct pharmacodynamic effects of excipients and the toxicity of oxidation byproducts, risking unforeseen clinical safety issues that extend beyond the API's profile.
Post-GLP-1 Metabolic Optimization
Amino-Peptide Matrices for Lean Mass Preservation in GLP-1 Receptor Agonist-Induced Gastroparesis
GLP-1 RA-induced gastroparesis and retained gastric contents present a significant challenge for effective oral nutrition delivery and lean mass preservation during weight loss therapy, especially in at-risk populations.
Precision Microbiome & Gut-Brain Axis
Gut-Brain Axis and Mental Illness: Microbiota, Mechanisms, and Testable Hypotheses
Translating complex gut-brain axis insights into effective, targeted formulations for psychiatric conditions requires addressing variable microbiome signatures, diverse mechanistic pathways, and inconsistent clinical trial outcomes.
Precision Microbiome & Gut-Brain Axis
The Neuroimmune Continuum: Mechanisms, Paradigm Shifts, and Translational Frontiers in Psychoneuroimmunology
Translating complex psychoneuroimmunological mechanisms, including BBB permeability, specific cytokine pathways, and targeted microglial modulation, into stable and bioavailable therapeutic formulations presents a significant CDMO hurdle.
Transmucosal Delivery & Dosage Form Engineering
Nutraceutical Pharmacokinetics: Advanced Delivery Systems for Improved Bioavailability
Many clinically relevant nutraceuticals exhibit poor oral bioavailability due to extensive first-pass metabolism and unfavorable physicochemical properties, making their therapeutic efficacy unpredictable in conventional forms.
Transmucosal Delivery & Dosage Form Engineering
Breakthroughs in Nutraceutical & Functional Food Technology: Delivery Systems, Green Manufacturing, and AI-Driven Precision Nutrition
Developing advanced nutraceuticals is challenged by low ingredient solubility, poor stability, and the lack of targeted or controlled release mechanisms, hindering optimal bioavailability and physiological efficacy. Ensuring robust evidence and regulatory acceptance for novel formulations further complicates development.
Precision Microbiome & Gut-Brain Axis
Pharmacomicrobiomics: Gut Microbiota Modulation of Drug Efficacy and Nutraceutical Biotransformation
Integrating the profound and variable metabolic capacity of the gut microbiome into pharmaceutical development to ensure consistent drug efficacy and bioavailability across diverse patient populations is a significant hurdle.
Transmucosal Delivery & Dosage Form Engineering
Piperine-Mediated Potentiation of Direct Oral Anticoagulants: A Clinically Unrecognized Hemorrhagic Risk
Piperine, marketed as a 'bio-enhancer' in nutraceuticals, dangerously potentiates DOACs by inhibiting P-gp and CYP3A4, leading to critical hemorrhagic risk due to uncontrolled increases in drug exposure. This unrecognized interaction demands safer alternatives for enhancing polyphenol bioavailability.
Post-GLP-1 Metabolic Optimization
Triple Agonists and Next-Generation Oral GLP-1s: Advancements in Metabolic Disorder Therapeutics
Formulating complex multi-receptor agonists and high-potency oral GLP-1 peptides requires advanced delivery systems to ensure bioavailability, stability, and patient adherence while mitigating gastrointestinal side effects.
Cerebral Bioenergetics & Neuro-Metabolic Rescue
Ketogenic Diet-Specified Interventions in Neurodegenerative Disease Mechanisms
Developing a formulation that achieves consistent and measurable ketosis while optimizing bioavailability and tolerability in neurodegenerative conditions is a key challenge.
Precision Microbiome & Gut-Brain Axis
Nutrition and Psychiatric Disorders: A Comprehensive Narrative Review of the Evidence Through 2026
Optimal dietary interventions for psychiatric disorders remain poorly standardized and show high variability in effectiveness.
Intracellular Defense & IV-Alternatives
Oxidative Stress Mitigation in Nutraceutical Stability: Packaging and Formulation Strategies
Nutraceutical dosage forms face significant degradation due to oxidative stress, driven by moisture, oxygen, and light. This presents a challenge for maintaining stability across supply-chain conditions and long shelf lives.
Precision Microbiome & Gut-Brain Axis
Enteric Delivery of Butyrate: Overcoming Gastrointestinal Barriers for Vagal Activation
Free butyrate salts dissolve prematurely in the upper gastrointestinal tract, limiting their availability for distal gut signaling. Additionally, their pungent odor and taste present significant challenges for patient adherence in chronic applications.
Post-GLP-1 Metabolic Optimization
Semaglutide: Gastrointestinal Effects and Post-Discontinuation Weight Regain, 2026
Developing GLP-1 formulations that balance robust metabolic benefits with reduced gastrointestinal side effects and mitigate post-discontinuation weight regain remains a significant challenge. The interplay between appetite modulation, gastrointestinal motility, and adverse event profiles adds complexity to product optimization.
Precision Microbiome & Gut-Brain Axis
Gut-Brain Axis in ADHD: Microbiota-Mediated Dopaminergic Pathway Modulation
Developing scientifically validated microbiome-targeted interventions for ADHD involves addressing the challenges of heterogeneity in clinical outcomes and identifying precise microbial mechanisms. Formulating stable, effective probiotics or synbiotics with demonstrated clinical benefits remains a major hurdle.
No dossiers match the selected MeSH topic in this page. Try another tag or clear the filter.
Custom Formulation Available
Need a Dossier Built Around Your Molecule?
Our R&D team will conduct a Paid Discovery Audit and build a proprietary clinical dossier for your specific active ingredient or therapeutic target. Full IP transfer included.